Loading...
Docoh

Oncocyte (OCX)

News

From Benzinga Pro
Oncocyte Presents DetermaIO Data At ASCO 2022 Supporting Test's Potential To Expand Clinical Use Of Immunotherapy
26 May 22
News, FDA
Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey,
Stocks That Hit 52-Week Lows On Tuesday
24 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Tuesday, 540 companies set new 52-week lows.
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
24 May 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Stephens & Co. Downgrades OncoCyte to Equal-Weight
24 May 22
News, Downgrades, Analyst Ratings
Stephens & Co. analyst Mason Carrico downgrades OncoCyte (NASDAQ:OCX) from Overweight to Equal-Weight.
Piper Sandler Maintains Overweight on OncoCyte, Lowers Price Target to $1.4
16 May 22
News, Price Target, Analyst Ratings
Piper Sandler analyst David Westenberg maintains OncoCyte (NASDAQ:OCX) with a Overweight and lowers the price target from $1.8 to $1.4.
Expert Ratings for OncoCyte
12 May 22
Analyst Ratings
Within the last quarter, OncoCyte (NASDAQ:OCX) has observed the following analyst ratings:
Needham Maintains Buy on OncoCyte, Lowers Price Target to $2.25
12 May 22
News, Price Target, Analyst Ratings
Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and lowers the price target from $4 to $2.25.
OncoCyte: Q1 Earnings Insights
11 May 22
Earnings
OncoCyte (NASDAQ:OCX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings OncoCyte reported in-line EPS of $-0.12 versus an estimate of $-0.12.
Earnings Scheduled For May 11, 2022
11 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
Stocks That Hit 52-Week Lows On Monday
25 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 721 companies achieved new lows for the year.
12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Apr 22
Movers
Gainers
2 Stocks Under $2 Insiders Are Aggressively Buying
19 Apr 22
Long Ideas, News, Penny Stocks, Insider Trades, Markets, Trading Ideas
Gold futures traded lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
4 Stocks Under $5 Insiders Are Aggressively Buying
18 Apr 22
Long Ideas, News, Penny Stocks, Insider Trades, Markets, Trading Ideas
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
14 Apr 22
Biotech, Government, News, Penny Stocks, Health Care, Financing, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:

Press releases

From Benzinga Pro
Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice
22 Jun 22
Health Care, Press Releases
IRVINE, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), is a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform
Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test's Potential to Expand the Clinical Use of Immunotherapy
26 May 22
News, Health Care, Press Releases
DetermaIO identifies responders to immunotherapy among the 95% of patients with colon cancer currently ineligible for treatment based on existing biomarker, addressing a significant unmet need DetermaIO test now
Oncocyte to Announce First Quarter 2022 Financial Results
28 Apr 22
News, Press Releases
IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical
Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™
27 Apr 22
News, Health Care, Press Releases
IRVINE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation��(NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical
Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants
13 Apr 22
News, IPOs, Press Releases
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), ("Oncocyte" or the "Company"), announced today the pricing of an underwritten public offering of 26,266,417 shares of its common
Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants
13 Apr 22
News, Financing, Press Releases
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), ("Oncocyte" or the "Company"), announced today that it has commenced an underwritten public offering of shares of its common stock,
Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock
13 Apr 22
Markets, Press Releases
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), ("Oncocyte" or the "Company"), a precision diagnostics company with the mission to improve patient outcomes by providing